Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 1/2014

Open Access 01-02-2014 | Topic Paper

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

Authors: Jens Bedke, Cécile Gouttefangeas, Harpreet Singh-Jasuja, Stefan Stevanović, Carl-Ludwig Behnes, Arnulf Stenzl

Published in: World Journal of Urology | Issue 1/2014

Login to get access

Abstract

Non-specific immunotherapy has been for a long time a standard treatment option for patients with metastatic renal cell carcinoma but was redeemed by specific targeted molecular therapies, namely the VEGF and mTOR inhibitors. After moving treatment for mRCC to specific molecular agents with a well-defined mode of action, immunotherapy still needs this further development to increase its accuracy. Nowadays, an evolution from a rather non-specific cytokine treatment to sophisticated targeted approaches in specific immunotherapy led to a re-launch of immunotherapy in clinical studies. Recent steps in the development of immunotherapy strategies are discussed in this review with a special focus on peptide vaccination which aims at a tumor targeting by specific T lymphocytes. In addition, different combinatory strategies with immunomodulating agents like cyclophosphamide or sunitinib are outlined, and the effects of immune checkpoint modulators as anti-CTLA-4 or PD-1 antibodies are discussed.
Literature
1.
Lokich J (1997) Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 20:416–418PubMedCrossRef
2.
Dengjel J et al (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12:4163–4170PubMedCrossRef
3.
Saenz-Lopez P et al (2010) Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. Tissue Antigens 75:110–118PubMedCrossRef
4.
Attig S et al (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69:8412–8419PubMedCrossRef
5.
Schendel DJ et al (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209–4220PubMed
6.
Ljungberg B et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406PubMedCrossRef
7.
8.
Atkins M et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714–3721PubMedCrossRef
9.
Pantuck AJ et al (2005) Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings No. 16S:4535
10.
Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409–2414PubMedCrossRef
11.
van der Vliet HJ et al (2007) Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 13:2100–2108PubMedCrossRef
12.
Kruck S et al (2012) Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 12:777–785PubMedCrossRef
13.
Escudier B et al (2012) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(suppl 7):vii65–71
14.
Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
15.
Hipp MM et al (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111:5610–5620PubMedCrossRef
16.
Finke JH et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674–6682PubMedCrossRef
17.
Ko JS et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157PubMedCrossRef
18.
Porta C et al (2011) Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer 2:333–338PubMedCentralPubMedCrossRef
19.
20.
Rammensee HG, Falk K, Rotzschke O (1993) Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11:213–244PubMedCrossRef
21.
van der Bruggen P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647PubMedCrossRef
22.
Weinschenk T et al (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62:5818–5827PubMed
23.
Seremet T, Brasseur F, Coulie PG (2011) Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 17:325–330PubMedCrossRef
24.
Brookman-May S et al (2011) Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev Vaccines 10:837–852PubMedCrossRef
25.
Wierecky J et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66:5910–5918PubMedCrossRef
26.
Biswas S, Eisen T (2009) Immunotherapeutic strategies in kidney cancer—when TKIs are not enough. Nat Rev Clin Oncol 6:478–487PubMedCrossRef
27.
Jocham D et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594–599PubMedCrossRef
28.
Wood C et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145–154PubMedCrossRef
29.
Escudier B (2012) Emerging immunotherapies for renal cell carcinoma. Ann Oncol 23(suppl 8):viii35–40
30.
Engels B et al (2005) Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum Gene Ther 16:799–810PubMedCrossRef
31.
Britten CM et al (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57:289–302PubMedCentralPubMedCrossRef
32.
van der Burg SH et al (2011) Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 3:108ps144
33.
34.
Walter S et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med in press
35.
Welters MJ et al (2010) Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 107:11895–11899PubMedCrossRef
36.
Amato RJ et al (2010) Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16:5539–5547PubMedCrossRef
37.
Sampson JH et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729PubMedCrossRef
38.
Feyerabend S et al (2009) Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69:917–927PubMedCrossRef
39.
Bedke J et al (2012) Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol Suppl 11:e76–eaCrossRef
40.
Uemura H et al (2006) A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 12:1768–1775PubMedCrossRef
41.
Rosenberg SA et al (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690–1695PubMedCentralPubMed
42.
Weber J et al (2003) Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97:186–200PubMedCrossRef
43.
44.
Kusmartsev S et al (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14:8270–8278PubMedCrossRef
45.
46.
Murdoch C et al (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618–631PubMedCrossRef
47.
48.
Yang JC et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825–830PubMedCentralPubMedCrossRef
49.
50.
51.
El Mir S, Triebel F (2000) A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 164:5583–5589PubMed
52.
Brignone C et al (2009) A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225–6231PubMedCrossRef
53.
Escudier B et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150PubMedCrossRef
54.
Rini BI et al (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28:2137–2143PubMedCrossRef
55.
56.
Figlin RA et al (2011) Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J Clin Oncol 29:(suppl; abstr 2532)
57.
Metadata
Title
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
Authors
Jens Bedke
Cécile Gouttefangeas
Harpreet Singh-Jasuja
Stefan Stevanović
Carl-Ludwig Behnes
Arnulf Stenzl
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 1/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-013-1033-3

Other articles of this Issue 1/2014

World Journal of Urology 1/2014 Go to the issue

Original Article

Quantifying subjective assessment of sleep quality, quality of life and depressed mood in children with enuresis

Topic Paper

The ineligible patient: how to treat patients not included in clinical studies

Original Article

Robotic-assisted laparoendoscopic single-site radical nephrectomy: first experience with the novel Da Vinci single-site platform

Editorial

Systemic therapy of renal cell carcinoma

Invited Review

How far is the horizon? From current targets to future drugs in advanced renal cancer

Original Article

Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome